David Lockhart is the founder of ReCode Therapeutics. ReCode Therapeutics has raised $145M in total funding. Latest round: Growth. Based in Menlo Park, CA.
David Lockhart is a biotechnology executive and scientist serving as President and Chief Scientific Officer (CSO) at ReCode Therapeutics, a genetic medicines company focused on pulmonary diseases. He joined ReCode in January 2022 following a merger that formed the new company, bringing expertise in precision medicine development. Prior to ReCode, he held leadership roles including CEO at Transcriptx, Inc. since 2014.
Full founder directory · Investor directory · Company funding database · Fundraising library